Can-Fite BioPharma (CANF) Free Cash Flow (2013)
Can-Fite BioPharma's (CANF) quarterly Free Cash Flow came in at -$1.7 million in Q3 2013.
Can-Fite BioPharma (CANF) Free Cash Flow (2013) Analysis & Trends
Can-Fite BioPharma (CANF) has 1 years of Free Cash Flow data on file, last reported at -$1.7 million in Q3 2013.
- Quarterly Free Cash Flow changed N/A year-over-year to -$1.7 million in Q3 2013, while the trailing twelve-month figure through Jun 2014 was -$1.7 million (changed N/A YoY) and the FY2025 annual result came in at -$9.0 million, down 17.13% from the prior year.
- Free Cash Flow was little changed at -$1.7 million in Q3 2013.
- In the past five years, Free Cash Flow ranged from a high of -$1.7 million in Q3 2013 to a low of -$1.7 million in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | -1.70 Mn |
| Sep 30, 2013 | -1.70 Mn |